USPTO Patent Application: Cancer Treatment with Anti-CD20 Antibody and Acylfulvenes

ChangeBridge: Patent Apps - Peptides (C07K)

Published December 1st, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083691A1) filed by Lantern Pharma Inc. The application describes a method for treating cancer by combining an anti-CD20 antibody with acylfulvenes. This patent application is related to novel therapeutic combinations for B-cell cancers.

View original document View source feed page

What changed

USPTO has published patent application US20260083691A1, filed by Lantern Pharma Inc., detailing a method for treating cancer. The invention involves administering a combination of an acylfulvene and an anti-CD20 antibody, such as rituximab or obinutuzumab, which may be effective against B-cell cancers.

This publication represents a new patent filing and does not impose immediate regulatory obligations on pharmaceutical companies. However, it signifies potential new intellectual property in cancer therapeutics, which may influence future drug development strategies and market exclusivity for companies operating in oncology and B-cell cancer treatment.

Source document (simplified)

← USPTO Patent Applications

TREATING CANCERS WITH COMBINATIONS OF ANTI-CD20 ANTIBODY AND ACYLFULVENES

Application US20260083691A1 Kind: A1 Mar 26, 2026

Assignee

Lantern Pharma Inc.

Inventors

Jianli Zhou, Kishor Bhatia

Abstract

A method of treating cancer includes administering a combination of active agents comprising a therapeutically effective amount of an acylfulvene, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an anti-CD20 antibody. The anti-CD20 antibody can be selected from rituximab, obinutuzumab, ofatumumab, and tositumomab. The cancer may be a B-cell cancer.